Effects of N-acetylcysteine on treatment of idiopathic sudden sensorineural hearing loss

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260304011

Enrollment

Registered

2026-03-04

Start date

2025-01-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effects of N-acetylcysteine on treatment of idiopathic sudden sensorineural hearing loss Sudden sensorineural hearing loss N-acetylcysteine Prednisolone Omeprazole PTA threshold SRT Speech recognition threshold SDS Speech discriminant score

Interventions

Treatment of idiopathic sudden sensorineural hearing loss by combination of Oral N-acetylcysteine and Prednisolone,Treatment of idiopathic sudden sensorineural hearing loss by Oral Prednisolone

Active Comparator Drug,No Intervention Drug

N-acetylcysteine,Control

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old 2. Unilateral sudden sensorineural hearing loss of at least 30dB for 3 contiguous frequencies. 3 Normal auditory brainstem response or MRI result.

Exclusion criteria

Exclusion criteria: 1. Diabetes Mellitus 2. Peptic ulcer 3. Middle or Inner ear diseases 4. Genetic-related hearing loss 5. History of ear surgery 6. Time to onset of more than 14 days 7. Prior treatment with corticosteroids in any form 8. Loss of follow up 9. Side effects from medications which disable the volunteer from continuing the medication 10. Medication non-adherence

Design outcomes

Primary

Measure	Time frame
Hearing threshold 2 weeks Audiometry	—

Secondary

Measure	Time frame
Speech recognition threshold 2 weeks Audiometry	—

Countries

Thailand

Contacts

Public ContactPanuwat Wongwattana

Srinakharinwirot university

panuwatw@gmail.com037395085

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026